Development of early dementia imaging marker by using a quantitative susceptibility mapping (QSM) and blood brain barrier (BBB) permeability imaging

Konkuk University Medical Center0 个研究点目标入组 75 人开始时间: 待定最近更新: 2023年6月26日

试验速览

暂无简介。

•Age 45 to 80 years old.
•- Individuals who have agreed to participate in the clinical trial and voluntarily signed the written informed consent form.
•- Patients who clinically correspond to the normal aging group or patients who meet the clinical diagnostic criteria for Mild Cognitive Impairment according to the 2011 NIA-AA (National Institute on Aging-Alzheimer's Association) guidelines.
•- Primarily, patients who have undergone an amyloid PET scan, if possible, are the primary targets.

•Exclusion criteria include individuals with a history of drug addiction, past or current neurological, psychiatric, neurosurgical diseases, or head trauma. Those who have taken psychiatric medications at doses higher than the therapeutic range that could affect brain waves in the past three months are also excluded. The study targets only individuals found to be free from dementia, based on a medical history survey, neurological examination, and cognitive function test conducted by a neurology specialist.

发起方